

1 Acute Type A Aortic Dissection in Adolescents and Young Adults 2 under 30 Years of Age: Demographics, Etiology and Postoperative 3 Outcomes of 139 cases

4
5 Maximilian Luehr¹, Murat Yildiz², Wei-Guo Ma³, Roland Heck⁴, Andreas Polycarpou⁵,
6 Arminder Jassar⁶, Maximilian Kreibich⁷, Daniel-Sebastian Dohle⁸, Gabriel Weiss⁹, Christian
7 Hagl^{10,11}, Filip Rega¹², Thomas Schachner¹³, Andreas Martens¹⁴, Alessandro Della Corte¹⁵,
8 Hiroaki Osada¹⁶, Li-Zhong Sun³, Konstantinos Tsagakis¹⁷, Florian Schoenhoff²

9
10 ¹Department of Cardiothoracic Surgery, HeartCenter, University of Cologne, Cologne, Germany

11 ²Department of Cardiovascular Surgery, University Hospital Bern, University of Bern, Switzerland

12 ³Anzhen Aortic Surgery, Capital Medical University, Beijing, China

13 ⁴Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Germany

14 ⁵Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA

15 ⁶Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, USA

16 ⁷Department of Cardiovascular Surgery, Faculty of Medicine, University Heart Center Freiburg—Bad Krozingen,
17 Germany

18 ⁸Department of Cardiothoracic and Vascular Surgery, University Hospital of Johannes Gutenberg University
19 Mainz, Mainz, Germany

20 ⁹Department of Cardiovascular Surgery, Clinic Floridsdorf, Vienna, Austria

21 ¹⁰Department of Cardiac Surgery, LMU University Hospital, Munich, Germany

22 ¹¹German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany

23 ¹²Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

24 ¹³Department for Operative Medicine, University Clinic for Cardiac Surgery, Medical University Innsbruck,
25 Innsbruck, Austria

26 ¹⁴Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover,
27 Germany

28 ¹⁵Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples, Italy

29 ¹⁶Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

30 ¹⁷Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center, University
31 Hospital Essen, Essen, Germany

32
33 **Word Count Total: 4988**

34 **Word Count Abstract: 243**

35 **Corresponding author:**

36 Maximilian Luehr, MD, PhD

37 Cardiothoracic Surgery

38 University of Cologne

39 Kerpener Str.62, 50937, Cologne, Germany

40 Phone:+49(0)22147832487

41 Fax:+49(0)22147832648

42 E-mail: maximilian.luehr@uk-koeln.de

1 **KEY QUESTION**

2 What is the prevalence and etiology of acute type A aortic dissection (AADA) in surgical
3 patients ≤ 30 years?
4
5

6 **KEY FINDINGS**

7 The overall prevalence in 7914 consecutive cases was 1.8% (n=139); Connective tissue
8 disease (36.7%) and arterial hypertension (33.1%) were the two most frequent risk factors for
9 AADA, while 9.4% of the cohort presented with a positive family history.
10
11

12 **TAKE-HOME MESSAGE**

13 The etiology of AADA is likely to be associated with connective tissue disease or arterial
14 hypertension in patients ≤ 30 years; open surgery may be performed with good short- and
15 excellent long-term survival in these patients.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **KEYWORDS:** acute aortic dissection; aortic surgery; connective tissue disease; Marfan
35 syndrome; Loeys-Dietz syndrome; Turner syndrome; genetic testing
36

1 **ABSTRACT**

2

3 **Background:**The prevalence and etiology of acute aortic dissection type A in patients ≤ 30
4 years is unknown. The aims of this clinical study were to determine the prevalence and
5 potential etiology of acute aortic dissection type A in surgically treated patients ≤ 30 years and
6 to evaluate the respective postoperative outcomes in this selective group of patients in a large
7 multi-centre study.

Methods:Retrospective data collection was performed at the 16 participating international
aortic institutions. All patients ≤ 30 years at the time of dissection onset were included. The
postoperative results were analysed with regard to connective tissue disease.

8

9 **Results:**The overall prevalence of acute aortic dissection type A ≤ 30 years was 1.8% (139 out
10 of 7914 patients), including 51(36.7%) patients who were retrospectively diagnosed with
11 connective tissue disease. Cumulative postoperative mortality was 8.6%, 2.2% and 1.4%,
12 respectively. Actuarial survival was 80% at 10 years postoperatively. Non- connective tissue
13 disease patients (n=88) had a significantly higher incidence of arterial hypertension
14 (46.6%vs.9.8%; $p < 0.001$) while acute aortic dissection type A affected the aortic root ($p < 0.001$)
15 and arch ($p = 0.029$) significantly more often in the connective tissue disease group. A positive
16 family history of aortic disease was present in 9.4% of the study cohort(n=13).

17

18 **Conclusions:**The prevalence of acute aortic dissection type A in surgically treated patients
19 ≤ 30 years is less than 2% with connective tissue disease and arterial hypertension as the two
20 most prevalent triggers of acute aortic dissection type A. Open surgery may be performed with
21 good early results and excellent mid- to long-term outcomes.

22

1 INTRODUCTION

2 Acute aortic dissection type A (AADA) remains associated with high mortality rates if
3 diagnosed too late or managed only medically[1–4]. Since the early beginnings of
4 cardiovascular surgery in the 1960s until today, the gold standard to address and potentially
5 cure this dreadful disease is open surgery[6]. Over the last decades, the available surgical
6 techniques and intraoperative management strategies evolved dramatically, comprising
7 selective cerebral and other organ perfusion strategies, application of more moderate body
8 core temperatures and the use of hybrid prostheses to reduce the duration and total number
9 of surgeries[7,8]. These developments allowed for significant reduction of the associated
10 mortality and morbidity rates, but still, AADA surgery may still result in postoperative mortality
11 rates of 5% to 28%, depending on the preoperative clinical condition and the experience of the
12 surgical team [1,2,5,7,9]. Prevention of AADA by routine follow-up imaging to allow for timely
13 surgery with regard to aortic diameter progression plays a key role in patients with known
14 aneurysm. However, AADA often occurs in the 6th and 7th life decade in individuals with
15 undiagnosed arterial hypertension and lower aortic diameters who are believed to be otherwise
16 healthy[10].

17 In the very young (≤ 30 years) the occurrence of AADA is rarely seen and, in general,
18 is believed to be related to connective tissue disease (CTD), aortic trauma or altered
19 mechanical stress of the aortic wall tissue associated with bicuspid aortic valves[11–13]. The
20 morbidity and mortality rates seem to be equally high compared to older patients. However,
21 the true prevalence and etiology of AADA in very young patients remain unknown.

22 Since there is scarce evidence in the literature on very young AADA patients, the aims
23 of this clinical study were to determine the prevalence and potential etiology of AADA in
24 surgically treated patients ≤ 30 years and to evaluate the respective postoperative outcomes in
25 this selective group of patients with regard to CTD in a large multi-centre study.

1 MATERIAL AND METHODS

2 3 *Study Population and Validation*

4
5 Data collection was performed retrospectively via a case report form (CRF) that had
6 been sent to each participating institution. The participating centres queried their databases
7 for patients ≤ 30 years of age and the total number of all patients that underwent surgery for
8 AADA. The study cohort (n=139) was divided into two study groups for further comparison with
9 regard to diagnosis of connective tissue disease: CTD group (n=51) and Non-CTD group
10 (n=88).

11 The collected data comprised the main baseline parameters for AADA at referral as
12 well as intra- and postoperative data with regard to surgical outcomes. Preoperative computed
13 tomography (CT) imaging allowed for determination of dissection extension and potential end-
14 organ malperfusion.

15 16 *Ethics statement*

17
18 The local Ethics Committees of the two lead study centres, Universites of Cologne (No.
19 20-1212) and Berne (KEK-2020-00851). Individual patient consent was waived due to the
20 retrospective design of the study.

21 22 *Definitions and Statistical Analysis*

23
24 In-hospital mortality was defined as any death before hospital discharge after surgery.
25 Preoperative lung and renal disease were defined as any clinically relevant impairment of the
26 respective organ systems. Genetic testing was performed according to the respective
27 institutional guidelines using their standardised gene panels. Patients with no or incomplete
28 testing were not included in the CTD group. Previous surgery was defined as any cardiac or
29 aortic operation prior to AADA onset. End-organ malperfusion was defined with regard to the
30 TEM classification as M0 (no malperfusion), M1 (coronary malperfusion), M2 (supraaortic
31 malperfusion) or M3 (spinal, visceral, iliac malperfusion). Clinical malperfusion was defined as
32 evident clinical symptoms of malperfusion of the respective organ-systems correlating with CT
33 imaging. Postoperative respiratory insufficiency was defined as prolonged ventilation (>7days),
34 need for re-intubation or tracheostomy. Renal insufficiency was defined with regard to
35 temporary or permanent need for dialysis. Postoperative stroke or paraplegia were only
36 counted if the neurologic damage occurred after surgery.

1 Categorical variables were reported using absolute and relative frequencies.
2 Continuous variables were expressed by mean (\pm standard deviation) or as median with
3 interquartile range (IQR; 25th-75th percentile). Tests between groups were performed using
4 chi-squared tests for categorical variables and *t*-tests for continuous variables. Since this is a
5 study of exploratory character, *p*-values were not adjusted for multiplicity and had to be
6 interpreted descriptively (*p*-values <0.05 were defined as statistically significant). The impact
7 of the available variables on in-hospital, 1- and 5-year mortality were analyzed using a
8 multivariable regression models. The binary logistic regression models were constructed with
9 the available variables and the risk factors with a *p*-value <0.1 (**Table4**). A two-tailed *p* <0.05
10 or less was considered to be statistically significant. Survival estimation was performed by the
11 Kaplan-Meier method. Statistical analyses were performed using SPSS software (version 27.0,
12 IBM, Armonk, NY,USA) for data analysis and visualization.

ACCEPTED MANUSCRIPT

1 RESULTS

2
3 Sixteen international aortic centres responded to the call of the EACTS Task Force for
4 Connective Tissue Disease and agreed to participate in this clinical study. Between the years
5 1997 and 2021, the total number of surgical AADA cases in the 16 available databases was
6 7914 with an overall prevalence of patients ≤ 30 years of 1.8% (n=139). The mean prevalence
7 of cases ≤ 30 years was $2.2(\pm 1.7)\%$ for the entire study group (**Figure1**). CTDs could be
8 diagnosed in 51(36.7%) patients. The mean follow-up time was 4.0 (± 2.5) years.

9 10 *Preoperative Demographics and Etiology*

11
12 The mean age of the entire study cohort was 25.6 ± 3.8 years and comprised mainly
13 males (75.5%) (**Figure 2**). Within the CTD group, Marfan syndrome was the most prevalent
14 CTD (n=44;86.2%), followed by Turner (7.8%) and Loeys-Dietz (5.9%) syndromes. The non-
15 CTD group showed significantly higher prevalences of arterial hypertension (46.6%vs.9.8%;
16 $p<0.001$) and renal disease (11.4%vs.0%; $p=0.013$), while a positive family history was
17 significantly more often present in the CTD group (17.7%vs.4.5%; $p=0.015$);with an overall
18 incidence of 9.4% for the entire study group. Moreover, no significant differences were found
19 between the CTD and non-CTD group (**Table1**).

20 Interestingly, only 6 (4.3%) out of the 139 study patients were younger than 18 years
21 (mean age 14.5 ± 2.1 years) suffering from CTD and arterial hypertension in 3 (50%) and 1
22 (17%) cases, respectively.

23 24 *Dissection-specific data*

25
26 The proximal thoracic aorta was significantly more often affected by AADA in the CTD
27 group: aortic root (84.3% vs. 56.8%; $p<0.001$), ascending aorta (98.0% vs. 83%; $p=0.005$) and
28 aortic arch (84.3% vs. 67.1%; $p=0.029$). No significant differences with regard to dissection
29 extension could be found further downstream of the aorta (**Supplemental table1**).

30 The most prevalent entry site was located in the ascending aorta (79.1%;E1), followed
31 by the aortic arch and root in 8.6%(E2) and 7.2%(E0), respectively. End-organ malperfusion
32 of the entire study group(n=139) was diagnosed with the TEM classification in 7.2% (M1),
33 7.2%(M2) and 10.1 (M3), respectively. Indicative clinical symptoms, with the exception of
34 coronary malperfusion, differed considerably from the TEM classification: coronary(7.9%),
35 cerebral(1.4%), visceral/spinal/iliac(16.6%). There were no significant differences regarding

1 entry tear locations and the incidence of end-organ malperfusion(TEM and clinical symptoms)
2 between the CTD and non-CTD groups (**Supplemental table1**).

3

4

ACCEPTED MANUSCRIPT

1 *Intraoperative data*

2
3 Aortic root replacement was significantly more often performed in the CTD group
4 (88.2% vs. 39.8%; $p < 0.001$), with the Bentall operation as the most preferred technique
5 (68.6% vs. 30.7%; $p < 0.001$). Valve sparing root replacement was also performed more
6 frequently in the CTD than in the non-CTD group but did not reach statistical significance
7 (19.6% vs. 9.1%; $p = 0.133$).

8 Total arch replacement—regardless of the surgical technique—was significantly more
9 often performed in CTD patients (49.0% vs. 31.8%; $p = 0.048$). The most frequent techniques
10 to address the aortic arch were hemiarch (30.9%), frozen elephant trunk (FET; 25.9%) and
11 classic total arch (no ET/FET; 10.8%) techniques. The CTD patients were treated more often
12 with non-hybrid arch replacements but without statistical significance (17.7% vs. 6.8%;
13 $p = 0.085$). The respective intra- and postoperative variables are depicted in **Table 2**.

14 15 *Postoperative outcomes*

16
17 Overall in-hospital mortality was 8.6% ($n = 12$) with no significant difference between the
18 CTD and non-CTD groups (9.8% vs. 8.0%; $p = 0.758$). Intraoperative death occurred in
19 4.4% ($n = 5$) while 3.0% ($n = 4$) died after a prolonged postoperative course on the intensive care
20 unit (ICU). The overall 1- and 5-year mortality rates were 2.2% and 1.4%, respectively. After 10
21 years, actuarial survival was 80% for both groups with no significant differences between the
22 CTD and non-CTD group (Log-rank/Mantle-Cox: $p = 0.646$) (**Figure 2**).

23 Postoperatively, the non-CTD patients showed higher incidences of respiratory
24 (13.6% vs. 5.9%; $p = 0.255$) and renal (13.6% vs. 9.8%; $p = 0.598$) insufficiency while neurologic
25 complications were equally distributed. No significant differences were found regarding
26 postoperative complications between the two study groups (**Table 3**).

27 28 *Risk factor analysis*

29
30 Univariate analysis revealed the following parameters as significant predictors of in-
31 hospital mortality: clinical malperfusion ($p = 0.028$), dissection extension beyond the iliac
32 bifurcation ($p = 0.015$), visceral ($p < 0.001$), lower extremity malperfusion ($p = 0.031$) as well as a
33 high ($\geq 11\%$) GERAADA score ($p < 0.001$). The predictors for 1-year mortality comprised TEM
34 classification M1 ($p = 0.007$), re-exploration for bleeding ($p = 0.023$), postoperative renal
35 insufficiency ($p = 0.040$) and temporary need for dialysis ($p = 0.017$). No significant predictors
36 were identified for 5-year mortality by univariate analysis (**Table 4**).

1 The single independent risk factor for in-hospital mortality identified by multivariable
2 analysis was the presence of an entry tear in the descending aorta (TEM:E3) for the entire
3 study cohort (OR17.411;95%-CI:1.547-195.937;p=0.021). In contrast, the absence of any end-
4 organ malperfusion (TEM classification M0) was independently protective for in-hospital
5 mortality (OR0.121;95%-CI:0.016-0.895,p=0.039). In addition, previous aortic surgery was
6 identified as an independent risk factor for 5-year mortality (OR44.667;95%-CI:2.227-
7 895.969;p=0.013). No independent risk factors for 1-year mortality were identified by
8 multivariable analysis (**Table 4**).

ACCEPTED MANUSCRIPT

1 DISCUSSION

2
3 Acute aortic dissection type A (AADA) usually occurs in the 6th or 7th decade of life and
4 is rarely seen in patients under 30 years of age[12]. Adolescents and young adults presenting
5 with AADA are a challenge for the surgeon on several levels. The optimal surgical strategy not
6 only has to ensure the immediate survival of the patient but also has to take a life expectancy
7 of several decades into account[16]. Due to the authors knowledge this is the first attempt to
8 focus on very young patients \leq 30 years that often are thought to be healthy until the immediate
9 and painful onset of AADA—with a prevalence of 1.8% in a large multi-centre cohort of almost
10 8000 surgical cases.

11 Interestingly, the vast majority of the study cohort were males (75.5%) with no
12 significant difference between patients with or without CTD. The prevalence of ascending
13 aortic aneurysm and bicuspid aortic valve (BAV) is known to be higher in males, while the
14 onset of aortic dissection may occur earlier and more extensively in females—potentially
15 resulting in worse outcomes compared to male patients[17]. In 2010, Détaint et al. showed an
16 increased risk for aortic dilation and aortic events in young (<30 years) Marfan males[18]. Most
17 recently, Nucera et al. also reported an increased overall incidence of aortic events in males
18 of up to 71% in a large series of 183 Marfan patients over a period of >25 years, including
19 acute type A and B aortic dissections in 14.1% and 12.6%, respectively[19]. In our study cohort,
20 the overall distribution of CTD and BAV did not significantly differ between male and female
21 patients suffering from AADA. Obviously, Turner syndrome was exclusively present among
22 female patients (11.8%; $p=0.003$) but no other significant gender specific differences, including
23 age of dissection onset and in-hospital mortality, were identified (**Supplemental table 2**).

24 Bicuspid aortic valve (BAV) as the most common congenital heart condition has a
25 reported incidence of 0.5-2.0% in the general population as well as in Marfan syndrome (1.8%)
26 [20]. Other authors reported a fourfold or even eightfold increased incidence of BAV in Marfan
27 and Loeys-Dietz syndrome, respectively[21]. In our study cohort, BAV patients had no positive
28 family history of aortic disease but almost one-fifth(18.8%) were also diagnosed with CTD,
29 which highlights the importance of differential genetic diagnosis by sequencing technologies
30 in BAV patients(**Supplemental table 3**).

31 Most interestingly, there was a positive family history in almost every 10th patient (9.8%)
32 of the 139 included cases. In the CTD group—representing more than one-third (36.7%) of the
33 entire study cohort—the incidence of a positive family history of aortic disease was significantly
34 increased (17.7%), potentially allowing for preoperative diagnosis and timely surgery in almost
35 every 5th patient suffering from CTD. The most frequent CTD identified was Marfan syndrome,
36 followed by Turner and Loeys-Dietz syndromes. Notably, no patient was diagnosed with any

1 form of Ehlers-Danlos syndrome. The current guidelines already recommend screening of all
2 1st degree relatives from patients presenting with thoracic aortic disease. These findings stress
3 the need for echocardiographic screening of relatives and genetic testing of patients with
4 thoracic aortic disease regardless of age which may help to avoid AADA in the first place[22].

5 Preoperatively, there was a significant difference between CTD and non-CTD patients
6 regarding the incidence of arterial hypertension. While the overall prevalence of arterial
7 hypertension was approximately one-third (33.1%) in the study cohort, almost half of the non-
8 CTD group was affected(46.6%). However, without CTD as the most obvious trigger for AADA
9 the authors of this study would have expected an even higher incidence or arterial hypertension
10 in the non-CTD group.

11 In the year 2000, the worldwide prevalence of arterial hypertension in young adults (20
12 to 29 years) was respectively estimated respectively to be 7.4% and 12.7% for females and
13 males, with a predicted increase of the prevalence of hypertension of 60% by the year
14 2025[23]. In the United States the estimated prevalence of patients aged 18-39 years between
15 2011 and 2012 was 7.3%. In addition, prevalence of an underlying cause—by means of
16 secondary hypertension—in affected young adults is reported to be only 5.3%, comprising
17 hypothyroidism (1.9%), renovascular disease (1.7%), renal insufficiency (1.5%), primary
18 hyperaldosteronism (1.2%), Cushing syndrome (0.5%), and pheochromocytoma (<0.3%)[24].
19 Most likely, the affected study patients suffered from undiagnosed arterial hypertension—with
20 increased risk for short- and mid-term cardiovascular adverse events—for a long time,
21 potentially allowing early diagnosis and subsequent medical treatment. However, the
22 awareness of an illness and a slower diagnosis rate may also play an important role here,
23 since regular primary care physician visits are usually lacking and potential symptoms, e.g.
24 headache, dizziness, etc., might be misinterpreted or dismissed by younger individuals[24,25].

25 The extension of AADA plays an important role in the preoperative planning of the
26 surgical strategy (e.g. choice of cannulation site, cerebral perfusion, hypothermic conditions,
27 etc.) and intraoperatively used operative techniques (e.g. hybrid vs. non-hybrid
28 prothesis)[26,27]. The CTD group showed significantly higher rates of proximal aortic
29 involvement, including the aortic root and arch, while the downstream aorta seemed equally
30 affected. Consequently, surgery of the root, either as a valve-sparing or Bentall operation, and
31 arch were required significantly more often in CTD patients. Some authors strongly suggest
32 that the aortic root and arch should be treated more aggressively in young AADA patients, and
33 especially when CTD is present, to avoid reoperations due to aortic valve regurgitation,
34 aneurysms and re-dissections on the long-term[28–30].

35 In comparison with the current literature, in-hospital mortality was exceptionally
36 low(8.6%) for the entire study group and did not significantly differ between the both groups

1 (9.8%vs.8.0%; $p=0.758$)—despite a more radical surgical approach on the proximal aorta in
2 the CTD group. The only independent risk factor identified for in-hospital mortality was an entry
3 tear in the descending aorta($n=6$)—which may either be due to retrograde type A aortic
4 dissection or just falsely identified re-entries. However, out of the six affected patients classified
5 as E3 by TEM, three underwent total arch surgery but only two received a FET procedure,
6 while the two patients who died in hospital had been treated with a hemiarch and ascending
7 replacement. The FET procedure is the gold standard in elective arch surgery to treat
8 aneurysms involving the distal arch and proximal descending aorta[31]. In AADA patients the
9 FET technique not only facilitates positive aortic remodeling in the postoperative course but
10 also may cover (re-)entry tears in the descending aorta[32]. However, some surgeons are
11 reluctant to use hybrid or endovascular stent grafts in patients with CTD[8]—which might
12 explain the slight trend toward more classic total arch replacements in the CTD group.

13 Malperfusion of end-organ systems has been widely recognized to be directly
14 associated with adverse outcomes in AADA patients[1,2,9]. This is in line with the identified
15 predictors of in-hospital mortality in this study, such as a high GERAADA score ($\geq 11\%$),
16 extensive dissection beyond the iliac artery bifurcation, presence of clinical symptoms and
17 visceral or lower extremity malperfusion. Naturally, the absence of end-organ malperfusion
18 (TEM: M0) is expected to result in significantly better outcomes and was shown to be
19 independently protective from in-hospital mortality in this study.

20 The respective short- and mid-term outcomes, with regard to mortality rates at 1 and 5
21 years, were excellent and also not significantly different between CTD and non-CTD patients.
22 In addition, actuarial survival at 10 years was still 80% for the entire cohort. Interestingly, no
23 independent risk factors for 1-year mortality could be identified by multivariable analysis
24 despite the several significant predictors from the univariate analysis, including coronary
25 malperfusion (M1), re-exploration for bleeding and postoperative renal insufficiency with need
26 for temporary dialysis. The overall incidence of postoperative complications did also not
27 significantly differ between the two study groups. However, non-CTD patients showed higher,
28 but not significantly increased, incidences of renal (13.6% vs. 5.9%) and respiratory
29 insufficiency (13.6% vs. 9.8%).

30 The only identified risk factor for 5-year mortality was previous aortic surgery. Although
31 the number of affected patients was low ($n=4$), previous aortic surgery was associated with a
32 44-fold increased mortality risk at five years and underlines the importance of ‘complete’
33 proximal aortic replacement at the primary operation. Aortic re-do surgery usually becomes
34 more difficult and often requires removal of old prosthetic or endovascular stent material, which
35 may even be more difficult in the hemodynamically unstable patient or in cases of excessive
36 bleeding due to AADA. As a consequence, surgery might be performed less extensively than

1 required, ultimately leaving the individual AADA patient at an increased risk for long-term
2 complications and aortic related death.

3 With regard to the postoperative early and mid-term results of this study, the authors
4 advocate for more extensive aortic root and arch replacement in patients ≤ 30 years (with or
5 without CTD), specifically with the use of the FET procedure if an entry or re-entry tear has
6 been diagnosed in the descending aorta. In addition, a thorough patient history and screening
7 of 1st degree relatives should be performed in all patients with thoracic aortic disease and/or
8 BAV to potentially identify CTDs and to prevent future AADA in collateral relatives.

9
10 *Limitations of the study*
11

12 The authors acknowledge that the retrospective design and descriptive character of the
13 presented study are major weaknesses and that the presented results have to be interpreted
14 with care. Moreover, genetic testing was not performed in all study patients as a routine
15 diagnostic procedure, leaving patients with no or incomplete testing in the Non-CTD group.
16 Information on re-operations during follow-up was not available from all participating centres
17 and therefore left out. However, the presented study is currently the largest cohort of AADA
18 patients ≤ 30 years and therefore, adds important insights to the cardiovascular community by
19 increasing the awareness and potentially improving the surgical treatment of AADA in the
20 adolescents and young adults.

ACCEPTED MANUSCRIPT

1 CONCLUSION

2 The prevalence of AADA in surgically treated patients ≤ 30 years is less than 2% with
3 CTD and arterial hypertension as two most frequent triggers. Surgery may be performed with
4 good results and excellent mid- to long-term outcomes. However, previous screening in
5 patients with phenotypic signs of CTD, BAV or a positive family history may have prevented
6 AADA in more than one-third of study patients.

8 Acknowledgements

9 The authors would like to thank the other members of the 'Dissections in the Young
10 Study Group' for their tremendous efforts and valuable contributions to this manuscript: Joscha
11 Buech, Tim Berger, Duke Cameron, Julia Dumfarth, Volkmar Falk, Stephen Gerfer, Kenji
12 Minatoya, Alberto Pochettino, Thoralf M. Sundt, Hendrik Treede, Lucas Van Hoof, Thorsten
13 Wahlers (alphabetical order).

14
15 **Funding:** None.

16
17 **Conflict of interest:** None.

18
19 **Data availability statement:** The datasets generated during and/or analysed during the
20 current study are available from the corresponding author on reasonable request.

TABLES:

Table1: Patient baseline characteristics

Parameters,n(%)	All patients (n=139)	CTD group (n=51)	No-CTD group (n=88)	p-value
Age(mean±SD)	25.6(±3.8)	25.2(±4.3)	25.8(±3.5)	0.372
Male gender	105(75.5%)	38(74.8%)	67(76.1%)	0.840
CAD	1(0.7%)	1(2.0%)		0.366
Hypertension	46(33.1%)	5(9.8%)	41(46.6%)	<0.001*
Lung disease	2(1.4%)		2(2.3%)	0.532
Renal disease	10(7.2%)		10(11.4%)	0.013*
Pos. family history	13(9.4%)	9(17.7%)	4(4.5%)	0.015*
Aortic aneurysm	26(18.7%)	12(23.5%)	14(15.9%)	0.270
Bicuspid aortic valve	16(11.5%)	3(5.8%)	13(14.8%)	0.167
CTD	51(36.7%)	51(100%)		<0.001*
Marfan	44(31.7%)	44(86.2%)		
Loeys-Dietz	3(2.2%)	3(5.9%)		
Turner	4(2.9%)	4(7.8%)		
Trauma	1(0.7%)		1(1.1%)	0.366
Preoperative Tamponade	5(3.6%)	3(5.9%)	2(2.3%)	0.356
Preoperative Neurology	7(5.0%)	1(2.0%)	6(6.8%)	0.422
Coma	1(0.7%)		1(1.1%)	0.366
Paraplegia	1(0.7%)		1(1.1%)	0.366
Minor peripheral	5(3.6%)	1(2.0%)	4(4.6%)	0.652
Previous cardiac surgery	5(3.6%)	-	5(5.7%)	0.158
AV replacement	2(1.4%)	-	2(2.3%)	0.532
MV repair	1(0.7%)	-	1(1.1%)	1.000
Congenital heart surgery	2(1.4%)	-	2(2.3%)	0.532
Previous aortic surgery	4(2.9%)	1(2.0%)	3(3.4%)	1.000
Valve sparing aortic root	1(0.7%)	-	1(1.1%)	1.000
Descending replacement	1(0.7%)	-	1(1.1%)	1.000
Abdominal replacement	1(0.7%)	-	1(1.1%)	1.000
TEVAR	1(0.7%)	1(2.0%)	-	0.366
GERAADA Score (±SD)	7.8(±3.4)%	7.8(±3.3)%	7.8(±3.4)%	1.000

CTD=connective tissue disease;SD=standard deviation;CAD=coronary artery disease;TEM=type,entry site,malperfusion;*=statistically significant

Table2: Intraoperative data

Parameters,n(%)	All patients (n=139)	CTD group (n=51)	No-CTD group (n=88)	p-value
Aortic replacement				
Root	80(57.6%)	45(88.2%)	35(39.8%)	<0.001*
Valve sparing	18(13.0%)	10(19.6%)	8(9.1%)	0.113
David	15(10.8%)	9(17.7%)	6(6.8%)	0.085
Yacoub	1(0.7%)	1(2.0%)		0.366
Other	2(1.4%)		2(2.3%)	0.298
Bentall	62(44.6%)	35(68.6%)	27(30.7%)	<0.001*
Ascending	130(93.5%)	48(94.1%)	82(93.2%)	1.000
Hemiarch	43(30.9%)	14(27.5%)	29(33.0%)	0.570
Total arch	53(38.1%)	25(49.0%)	28(31.8%)	0.048*
Total(noET/FET)	15(10.8%)	9(17.7%)	6(6.8%)	0.085
Elephant trunk	2(1.4%)	1(2.0%)	1(1.2%)	1.000
FET	36(25.9%)	15(29.4%)	21(23.9%)	0.547
Descending	1(0.7%)		1(1.2%)	1.000
Concomitant procedures	8(5.8%)	1(2.0%)	7(8.0%)	0.257
CABG	6(4.3%)	1(2.0%)	5(5.7%)	0.414
ASD closure	1(0.7%)	-	1(1.2%)	1.000
Mitral valve repair	1(0.7%)	-	1(1.2%)	1.000

ET= Elephant trunk;FET=Frozen ET;AVR=aortic valve replacement; *=statistically significant

Table3: Postoperative outcomes

Parameters,n(%)	All patients (n=139)	CTD group (n=51)	No-CTD group (n=88)	p-value
In-hospital mortality	12(8.6%)	5(9.8%)	7(8.0%)	0.758
Intraoperative	5(4.4%)	2(3.9%)	3(3.4%)	1.000
Postoperative	7(3.0%)	3(5.9%)	4(4.6%)	0.707
Follow-up mortality	9(6.5%)	4(7.8%)	5(5.7%)	0.724
1-year mortality	3(2.2%)		3(3.4%)	0.553
5-year mortality	2(1.4%)	1(2.0%)	1(1.4%)	1.000
Cumulative mortality	21(15.1%)	9(17.6%)	12(13.6%)	0.624
Re-exploration	13(9.4%)	5(9.8%)	8(9.1%)	1.000
Respiratory insufficiency	15(10.8%)	3(5.9%)	12(13.6%)	0.255
Ventilation(>7d)	5(3.6%)	2(3.9%)	3(3.4%)	1.000
Reintubation	3(2.2%)	1(2.0%)	2(2.3%)	1.000
Tracheostomy	7(5.0%)	1(2.0%)	6(6.8%)	0.422
Renal insufficiency	17(12.2%)	5(9.8%)	12(13.6%)	0.598
Temporary dialysis	11(7.9%)	3(5.9%)	8(9.1%)	0.746
Permanent dialysis	4(2.9%)	1(2.0%)	3(3.4%)	1.000
Stroke	4(2.9%)	2(3.9%)	2(2.3%)	0.624
Paraplegia	4(2.9%)	2(3.9%)	2(2.3%)	0.624

CTD=connective tissue disease;d=days;*=statistically significant

Table4: Predictors and risk factors for in-hospital 1-year and 5-year mortality by univariate and multivariable regression for the entire study cohort(n=139)

Parameters				p-value
Univariate analysis				
<i>In-hospital mortality</i>				
TEM classification E3				0.086
TEM classification M0				0.085
Clinical malperfusion				0.028*
Dissection extension iliac arteries				0.015*
Preoperative coma				0.086
Visceral malperfusion				<0.001*
Lower extremity malperfusion				0.031*
High GERAADA score				<0.001*
<i>1-year mortality</i>				
TEM classification M1				0.007*
Re-exploration for bleeding				0.023*
Postoperative renal insufficiency				0.040*
Temporary need for dialysis				0.017*
<i>5-year mortality</i>				
Previous aortic surgery				0.057
Multivariable analysis				
	Odds ratio	95%-Confidence interval		p-value
		low	high	
<i>30-day mortality</i>				
TEM classification E3	17.411	1.547	195.937	0.021*
TEM classification M0	0.121	0.016	0.895	0.039*
<i>5-year mortality</i>				
Previous aortic surgery	44.667	2.227	895.969	0.013*

TEM=type,entry site,malperfusion.*=statistically significant

1 **FIGURE LEGEND:**

2

3 **Central image:** Prevalence of acute aortic dissection in patients ≤ 30 in all study centres

4

5 **Figure1:** Respective case numbers and distribution with regard to age (≤ 30 vs. ≥ 31 years)

6 from all study centres.

7

8 **Figure2:** Age distribution of the study cohort (n=139). Red dot equals mean age (25.6 years).

9

10 **Figure3:** Survival estimation by Kaplan-Meier method for the entire study cohort (A; n=139)

11 and the two study groups (B): CTD (blue; n=55) vs. non-CTD (green; n=88).

12

ACCEPTED MANUSCRIPT

1 REFERENCES


- 2
- 3 1. Okita Y. The sooner the better? Early strategies of peripheral vascular intervention for
4 patients with acute aortic dissection complicated by organ malperfusion. *J Thorac
5 Cardiovasc Surg.* 2018 Aug; 156(2):490–1.
- 6 2. Girdauskas E, Kuntze T, Borger MA, Falk V, Mohr FW. Surgical risk of preoperative
7 malperfusion in acute type A aortic dissection. *J Thorac Cardiovasc
8 Surg.* 2009 Dec; 138(6):1363–9.
- 9 3. Bachet J. Acute type A aortic dissection: can we dramatically reduce the surgical
10 mortality? *Ann Thorac Surg.* 2002 Mar; 73(3):701–3.
- 11 4. Harris KM, Nienaber CA, Peterson MD, Woznicki EM, Braverman AC, Trimarchi S, et al.
12 Early Mortality in Type A Acute Aortic Dissection. *JAMA Cardiol.* 2022 Aug 24;
- 13 5. Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem U, et al.
14 Insights From the International Registry of Acute Aortic Dissection: A 20-Year
15 Experience of Collaborative Clinical Research. *Circulation.* 2018 Apr 24; 137(17):1846–
16 60.
- 17 6. DeBakey ME, Henly WS, Cooley DA, Morris GC, Crawford ES, Beall AC. Surgical
18 management of dissecting aneurysms of the aorta. *J Thorac Cardiovasc
19 Surg.* 1965 Jan; 49:130–49.
- 20 7. Shrestha M, Haverich A, Martens A. Total aortic arch replacement with the frozen
21 elephant trunk procedure in acute DeBakey type I aortic dissections. *Eur J
22 Cardiothorac Surg.* 2017 Jan; 51(suppl 1):i29–34.
- 23 8. Czerny M, Schmidli J, Adler S, Berg JC, Bertoglio L, Carrel T, et al. Current options and
24 recommendations for the treatment of thoracic aortic pathologies involving the aortic
25 arch. *Eur J Cardio-Thorac Surg.* 2019 Jan 1; 55(1):133–62.
- 26 9. Geirsson A, Szeto WY, Pochettino A, McGarvey ML, Keane MG, Woo YJ, et al.
27 Significance of malperfusion syndromes prior to contemporary surgical repair for


- 1 acute type A dissection *Eur J Cardiothorac Surg.* 2007 Aug; 32(2):255–62.
- 2 10. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014
3 ESC Guidelines on the diagnosis and treatment of aortic diseases. *Eur Heart J.*
4 2014 Nov 1; 35(41):2873–926.
- 5 11. Haunschild J, Dietze Z, Kampen A, Magomedov K, Misfeld M, Leontyev S, et al. Aortic
6 root replacement in bicuspid versus tricuspid aortic valve patients. *Ann Cardiothorac*
7 *Surg.* 2022 Jul; 11(4):436–47.
- 8 12. Rylski B, Hoffmann I, Beyersdorf F, Suedkamp M, Siepe M, Nitsch B, et al. Acute aortic
9 dissection type A: age-related management and outcomes reported in the German
10 Registry for Acute Aortic Dissection Type A (GERAADA) of over 2000 patients. *Ann*
11 *Surg.* 2014 Mar; 259(3):598–604.
- 12 13. Schoenhoff FS, Alejo DE, Black JH, Crawford TC, Dietz HC, Grimm JC, et al.
13 Management of the aortic arch in patients with Loeys-Dietz syndrome. *J Thorac*
14 *Cardiovasc Surg.* 2020 Nov; 160(5):1166–75.
- 15 14. Luehr M, Wahlers T. Predictive risk scores for patients with acute type A aortic
16 dissection: Magic 8-Ball or inconvenient truth? *Eur J Cardio-Thorac*
17 *Surg.* 2022 Jan 24; 61(2):386–7.
- 18 15. Anderson NK, Juzwiak EE, Dietz HC. A sex(X/Y) Article on Marfan Syndrome. *J Am*
19 *Heart Assoc.* 2020 Oct 20; 9(20):e018814.
- 20 16. Détaint D, Faivre L, Collod-Beroud G, Child AH, Loeys BL, Biquet C, et al.
21 Cardiovascular manifestations in men and women carrying a FBN1 mutation. *Eur*
22 *Heart J.* 2010 Sep; 31(18):2223–9.
- 23 17. Nucera M, Heinisch PP, Langhammer B, Jungi S, Mihalj M, Schober P, et al. The impact
24 of sex and gender on aortic events in patients with Marfan syndrome. *Eur J Cardio-*
25 *Thorac Surg.* 2022 May 11; ezac305.
- 26 18. Milleron O, Ropers J, Arnoult F, Bouleti C, Delorme G, Langeois M, et al. Clinical
27 Significance of Aortic Root Modification Associated With Bicuspid Aortic Valve in


- 1 Marfan Syndrome. *Circ Cardiovasc Imaging*.2019 Mar;12(3):e008129.
- 2 19. Giusti B,Sticchi E,DeCario R,Magi A,Nistri S,Pepe G.Genetic Bases of Bicuspid Aortic
3 Valve:The Contribution of Traditional and High-Throughput Sequencing Approaches
4 on Research and Diagnosis.*Front Physiol*.2017;8:612.
- 5 20. Nienaber CA,Clough RE,Sakalihasan N,Suzuki T,Gibbs R,Mussa F,et al. Aortic
6 dissection. *Nat Rev Dis Primer*.2016Jul21;2:16053.
- 7 21. Kearney PM,Whelton M,Reynolds K,Muntner P,Whelton PK,He J.Global burden of
8 hypertension: analysis of worldwide data. *Lancet Lond Engl*.
9 2005Jan15;365(9455):217–23.
- 10 22. Hinton TC,Adams ZH,Baker RP,Hope KA,Paton JFR,Hart EC,et al. Investigation and
11 Treatment of High Blood Pressure in Young People:Too Much Medicine or
12 Appropriate Risk Reduction? *Hypertens Dallas Tex*1979.2020 Jan;75(1):16–22.
- 13 23. Huguet N,Larson A,Angier H,Marino M,Green BB,Moreno L,et al. Rates of
14 Undiagnosed Hypertension and Diagnosed Hypertension Without Anti-hypertensive
15 Medication Following the Affordable Care Act.*Am J Hypertens*.
16 2021Sep22;34(9):989–98.
- 17 24. Peterss S,Pichlmaier M,Curtis A,Luehr M,Born F,Hagl C. Patient management in
18 aortic arch surgery†. *Eur J Cardiothorac Surg*.2017Jan;51(suppl 1):i4–14.
- 19 25. Luehr M,Bachet J,Mohr FW,Etz CD. Modern temperature management in aortic arch
20 surgery: the dilemma of moderate hypothermia. *Eur J Cardio-Thorac*
21 *Surg*.2014Jan;45(1):27–39.
- 22 26. Bachet J.Acute type A dissection-Should we systematically replace the aortic root? *J*
23 *Thorac Cardiovasc Surg*.2021Feb;161(2):495–6.
- 24 27. Khachatryan Z,Herajärvi J,Leontyev S,Borger MA. Valve-sparing aortic root
25 replacement can be done safely and effectively in acute type A aortic dissection. *J*
26 *Thorac Cardiovasc Surg*.2022Sep;164(3):814–9.
- 27 28. Liakopoulos OJ, Choi YH. Progressive aortic valve regurgitation after replacement of

- 1 the dissected ascending aorta:An unsolved dilemma. J Thorac Cardiovasc Surg.2020
2 Dec;160(6):1432–3.
- 3 29. Shrestha M,Bachet J,Bavaria J,Carrel TP,DePaulis R,DiBartolomeoR,et al. Current
4 status and recommendations for use of the frozen elephant trunk technique.Eur J
5 Cardio-Thorac Surg.2015May;47(5):759–69.
- 6 30. Dohle DS,Tsagakis K,Janosi RA,Benedik J,Kühl H,Penkova L,et al. Aortic remodelling
7 in aortic dissection after frozen elephant trunk†. Eur J Cardio-Thorac
8 Surg.2016Jan;49(1):111–7.
- 9

ACCEPTED MANUSCRIPT








ACCEPTED MANUSCRIPT

Prevalence of AADA \leq 30 years



Centre ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
■ \geq 31 years	501	527	444	78	1317	78	438	566	859	352	507	613	201	283	512	494
■ \leq 30 years	4 (0.8%)	6 (1.1%)	4 (0.9%)	4 (5.1%)	12 (0.9%)	2 (2.6%)	8 (1.8%)	7 (1.2%)	10 (1.2%)	11 (3.1%)	11 (2.6%)	5 (0.8%)	8 (4.0%)	3 (1.1%)	38 (7.4%)	11 (2.3%)

Number of AADA cases

ACCEPTED MANUSCRIPT